Full video transcriptClick to expand
Auto-generated transcript of @journeyto150marthaf's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:00Good morning. This is day seven on semi-glutide and I just laid myself.
- 0:06I am completely shocked on how amazing semi-glutide has worked with me in my body.
- 0:11I feel like I am adapting and learning really really quickly what works for me and what doesn't
- 0:17as far as food because I will say that there are certain foods that just make me nauseous
- 0:22a lot more than others. I'm already starting to see such a big difference in my face even in just
- 0:28one week. I feel so much lighter. I feel less puffy. I feel less bloated and I don't feel super
- 0:36hungry which is amazing. This is what I made for breakfast and honestly I was only able to eat half
- 0:41of this. This is the end of week one and I've lost 10.2 pounds. Follow me and see how week two is going.
Semaglutide early weight loss: what's real vs. water weight?
Quick answer
The creator is documenting early semaglutide use, reporting appetite suppression, food-specific nausea, and 10.2 pounds of scale weight loss at day seven. These are consistent with the known pharmacodynamics of GLP-1 receptor agonists, but early scale changes on this class of medication are substantially influenced by reduced glycogen stores and associated water loss, not fat oxidation alone. Food-triggered nausea is a common adverse effect in the titration phase and often guides patients toward lower-fat, lower-sugar diets that compound the early weight reduction.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Compounded Semaglutide access requires the right clinical path
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 7 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Semaglutide early weight loss: what's real vs. water weight?, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.
PubMed
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus
Used for pages discussing stopping therapy, weight regain, and long-term planning.
PubMed
Video claim decision path
Turn the claim into a safer next question
Direct answer
Compounded Semaglutide should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.
Evidence check
Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.
Safety check
A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.
Next step
If the claim matches your goal, use the get-started flow to move from curiosity into a supervised prescription review.
Claim path
Keep researching this semaglutide video claims cluster
Best for searchers comparing social semaglutide claims with GLP-1 eligibility, outcomes, and safety context.
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "Semaglutide early weight loss: what's real vs. water weight?" from Journey to 150 | Martha F ♥️. We read the clip as a GLP-1 social video fact-checks claim about Compounded Semaglutide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: The creator is documenting early semaglutide use, reporting appetite suppression, food-specific nausea, and 10.
The reason this review is not generic is the source wording and the canonical claim label "glp1 this weightloss journey has just begun and i m already in aw." In this clip, the useful excerpt is: "Good morning." That wording changes the review because it points to Compounded Semaglutide safety, access, evidence, and fit, not a one-size-fits-all protocol.
The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. Compounded Semaglutide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
The creator is documenting early semaglutide use, reporting appetite suppression, food-specific nausea, and 10.
FormBlends verdict
Compounded Semaglutide safety, access, evidence, and fit
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with the Compounded Semaglutide guide, safety notes, access rules, and a licensed-provider review.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- The creator is documenting early semaglutide use, reporting appetite suppression, food-specific nausea, and 10.2 pounds of scale weight loss at day seven. These are consistent with the known pharmacodynamics of GLP-1 receptor agonists, but early scale changes on this class of medication are substantially influenced by reduced glycogen stores and associated water loss, not fat oxidation alone. Food-triggered nausea is a common adverse effect in the titration phase and often guides patients toward lower-fat, lower-sugar diets that compound the early weight reduction.
- The STEP 1 trial (Wilding et al., 2021, NEJM) showed 14.9% average body weight loss over 68 weeks on semaglutide 2.4mg, not in weeks.
- Early scale drops on GLP-1 medications are largely water and glycogen loss. Each gram of glycogen is stored with roughly 3 grams of water, making rapid early losses common but not indicative of fat loss.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compounded Semaglutide decisions still need source quality, legal access, and provider oversight checks.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against the Compounded Semaglutide guide, cost path, safety notes, and provider review before acting.
Review Compounded SemaglutideWhat You'll Learn
- The STEP 1 trial (Wilding et al., 2021, NEJM) showed 14.9% average body weight loss over 68 weeks on semaglutide 2.4mg, not in weeks.
- Early scale drops on GLP-1 medications are largely water and glycogen loss. Each gram of glycogen is stored with roughly 3 grams of water, making rapid early losses common but not indicative of fat loss.
- Nausea is the most frequently reported early adverse effect on semaglutide, documented in over 40% of patients during titration in clinical trials (Davies et al., 2021, Diabetes Care).
- Appetite suppression through hypothalamic GLP-1 receptors and slowed gastric emptying is pharmacologically real and begins within the first week of use.
- Visible changes in facial puffiness after seven days are most likely explained by reduced caloric and sodium intake, not a direct drug mechanism.
- Patients who do not see double-digit week-one losses should not conclude the medication has failed. Fat loss becomes more evident after the initial fluid changes stabilize.
- GLP-1 medications require a clinician's supervision. Individual response varies based on starting weight, metabolic health, and titration schedule.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What did @journeyto150marthaf actually say?
On day seven of semaglutide, this creator reported losing 10.2 pounds, feeling "less puffy," "less bloated," and "not super hungry." She also noticed she could only eat half her breakfast and that certain foods were making her nauseous more than others.
To be clear, she was not making wild medical claims. She said she was "adapting and learning" what works for her body, which is actually a reasonable way to frame early GLP-1 experience. She did not promise anyone else the same results, and she did not recommend a dose or a specific protocol. This is personal experience content, not a how-to guide, and that distinction matters when evaluating it.
Still, 10.2 pounds in seven days is a number that deserves scrutiny, because it will register as a benchmark for everyone watching. And some of the things she attributed to semaglutide, such as reduced puffiness and feeling lighter, have a more complicated explanation than the drug alone.
Does the science back this up?
Yes and no. Rapid early weight loss on semaglutide is real, but most of week one is not fat loss. The suppressed appetite is pharmacologically real, but the "less bloated" and "less puffy" effects are largely about fluid and food volume, not the drug specifically.
The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) showed an average of 14.9% body weight reduction over 68 weeks on 2.4mg semaglutide weekly, but the loss in week one was not broken out separately because that is not how clinical trials measure outcomes. What we do know from gastric emptying research is that semaglutide slows how quickly the stomach clears food, which reduces meal size tolerance, which reduces caloric intake fast. That part is real.
The early scale drop, however, is heavily influenced by reduced carbohydrate intake and lower food volume, both of which cause glycogen and water to leave the body. For every gram of glycogen stored, roughly 3 grams of water are stored alongside it. If you are suddenly eating half your breakfast and avoiding heavier foods, you will lose several pounds of water weight in days. That is not a lie, but it is not the same as fat loss either.
What did they get wrong (or right)?
She got the appetite suppression right. The nausea pattern she described, where certain foods trigger it more than others, is well-documented. High-fat and high-sugar foods are the most common culprits on GLP-1 medications, and learning to work around them is genuinely useful early-stage behavior.
Where the video gets slippery is the face and puffiness observation. "I'm already starting to see such a big difference in my face" after seven days is almost certainly reflecting reduced sodium intake and lower food volume, not semaglutide directly reshaping her face. The drug did not do that in a week. Eating less did.
The 10.2-pound number is not wrong, but presenting it without context, specifically that a significant portion is likely water and glycogen, is where creators unintentionally mislead their audiences. People see that number and set it as a week-one expectation. That is where the harm sits, not in anything she did wrong personally, but in what gets left out.
- Appetite suppression by day seven: consistent with GLP-1 mechanism of action
- Nausea with specific foods: documented in clinical practice and patient-reported outcomes
- 10+ pounds in one week: plausible but predominantly water weight, not fat
- Visible facial changes in seven days: not attributable to semaglutide directly
What should you actually know?
Early weight loss on semaglutide is real, but it is not representative of what the drug does over time. The first one to two weeks often produce outsized numbers for reasons that have little to do with fat metabolism.
A 2022 systematic review by Shi et al. in Obesity Reviews confirmed that GLP-1 receptor agonists reduce appetite and food intake through central and peripheral mechanisms, including slowing gastric emptying and acting on hypothalamic satiety pathways. That mechanism is legitimate. What it does not do in week one is mobilize 10 pounds of fat. At a caloric deficit of even 1,000 calories per day, you would lose about two pounds of fat in a week. The rest of that number is fluid.
This matters because people who do not see 10 pounds in their first week sometimes conclude the medication is not working, when in reality their body composition may be changing more favorably than the scale reflects. Setting realistic expectations from the start is not pessimism. It is how you stay on the medication long enough for it to actually work.
If you are considering a GLP-1 medication, speak with a licensed clinician. Results vary based on starting weight, metabolic health, diet, and which specific medication is prescribed.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Journey to 150 | Martha F ♥️ · TikTok creator
6.3K views on this video
This weightloss journey has just begun and i’m already in awe! This week I have learned a lot about portion control, and the types of food that make me nauseous with this medication. I am in complete shock that I’ve already lost 10.2 pounds. I will say it’s very difficult to believe it even though I am already seeing a difference. I invite you to follow my journey to 150 pounds! ♥️⚖️ ##healthweightloss##newme##semaglutide##weightlossjouney##weightloss##foryou
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about the step 1 trial (wilding et al., 2021, nejm) showed?
The STEP 1 trial (Wilding et al., 2021, NEJM) showed 14.9% average body weight loss over 68 weeks on semaglutide 2.4mg, not in weeks.
What does the video say about early scale drops on glp-1 medications?
Early scale drops on GLP-1 medications are largely water and glycogen loss. Each gram of glycogen is stored with roughly 3 grams of water, making rapid early losses common but not indicative of fat loss.
What does the video say about nausea?
Nausea is the most frequently reported early adverse effect on semaglutide, documented in over 40% of patients during titration in clinical trials (Davies et al., 2021, Diabetes Care).
What does the video say about appetite suppression through hypothalamic glp-1 receptors?
Appetite suppression through hypothalamic GLP-1 receptors and slowed gastric emptying is pharmacologically real and begins within the first week of use.
What does the video say about visible changes in facial puffiness after seven days?
Visible changes in facial puffiness after seven days are most likely explained by reduced caloric and sodium intake, not a direct drug mechanism.
What does the video say about patients who do not see double-digit week-one losses should not?
Patients who do not see double-digit week-one losses should not conclude the medication has failed. Fat loss becomes more evident after the initial fluid changes stabilize.
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Journey to 150 | Martha F ♥️, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.